Hereditary prostate cancer

BJU International

Volumn 85, Issue 5, 2000, Pages 588-598

  Bratt, O ^a,b  

^a HELSINGBORG HOSPITAL   (Sweden)

^b Helsingborg General Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

COUNSELING; DISTRESS SYNDROME; FAMILIAL CANCER; FAMILY HISTORY; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

BRCA2 PROTEIN; GENES, BRCA1; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MUTATION; NEOPLASM PROTEINS; PEDIGREE; PROSTATIC NEOPLASMS; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0034087640     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00457.x     Document Type: Review

References (107)

1. 1 Wartin A. Heredity with reference to carcinoma. Arch Int Med 1913; 12: 546-55
2. 2 Wolff J. Die Lehre von der Krebskrankheit von den äldsten Zeiten bis zur Gegenwart. Jena: Gustav Fleischer 1907
3. 3 Broca P. Traite des tumeurs. Paris: Asselin 1866
4. 4 Lynch H, Shaw M, Magnuson C, Larsen A, AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Int Med 1966; 117: 206-12
5. 5 Li F, Fraumeni J. Soft tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71: 747-52
6. 6 Knudson A. Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-3
7. 7 Hogg A, Bia B, Onadim Z, Cowell J. Molecular mechanisms of oncogenetic mutations in tumours from patients with bilateral and unilateral retinoblastoma. Proc Natl Acad Sci USA 1993; 90: 7351-5
8. 8 Eeles R, Ponder B, Easton D, Horwich A. Genetic Predisposition to Cancer, 1st edn. Oxford: Chapman & Hall, 1996
9. 9 Houlston R, Peto J. Genetics and the common cancers. In Eeles R, Ponder B, Easton D, Horwich A, eds. Genetic Predisposition to Cancer. London: Chapman & Hall, 1996: 208-26
10. 10 Watson P, Lin K, Rodriguez-Bigas M et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 1998; 83: 259-66
11. 11 Marcus J, Watson P, Page D et al. Hereditary breast cancer. Pathology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697-709
12. 12 Rubin S, Benjamin I, Behbakht K, Takahashi H. Clinical and pathological features of ovarian cancer in women with germ-line mutations in BRCA1. N Engl J Med 1996; 335: 1413-6
13. 13 Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-9
14. 14 Cowell J. Retinoblastoma: the paradigm for genetically inherited cancer. In Eeles R, Ponder B, Easton D, Horwich A, eds. Genetic Predisposition to Cancer. London: Chapman & Hall, 1996: 58-69
15. 15 Blackwood M, Weber B. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998; 16: 1969-77
16. 16 Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. Brca1 and Brca2. JAMA 1997; 277: 997-1003
17. 17 Burke W, Petersen G, Lynch P et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I Hereditary non-polyposis colon cancer. JAMA 1997; 277: 915-9
18. 18 Fisher B, Costantino J, Wickerham D et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88
19. 19 Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101
20. 20 Kash KM, Holland JC, Halper MS, Miller DG. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 1992; 84: 24-30
21. 21 Lloyd S, Watson M, Waites B et al. Familial breast cancer: a controlled study of risk perception, psychological morbidity and health beliefs in women attending for genetic counselling. Br J Cancer 1996; 74: 482-7
22. 22 McCaul K, O'Donnell S. Naive beliefs about breast cancer risk. Women's Health 1998; 4: 93-101
23. 23 Bratt O, Damber J-E, Emanuelsson M et al. Risk perception, screening practice, and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer, in press
24. 24 American Society of Clinical Oncology A. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996; 14: 1730-6
25. 25 Lerman C, Rimer B, Engstrom P. Cancer risk notification: psychosocial and ethical implications. J Clin Oncol 1991; 9: 1275-82
26. 26 Lerman C, Hughes C, Lemon J et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 1998; 16: 1650-4
27. 27 Watson M, Lloyd S, Eeles R et al. Psychosocial impact of testing (by linkage) for the BRCA1 breast cancer gene: an investigation of two families in the research setting. Psycho-Oncol 1996; 5: 233-9
28. 28 Carter B, Bova G, Beaty T et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802
29. 29 Keetch D, Humphrey P, Smith D, Stahl D, Catalona W. Clinical and pathological features of hereditary prostate cancer. J Urol 1996; 155: 1841-3
30. 30 Bratt O, Kristoffersson U, Lundgren R, Olsson H. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer 1999; 35: 272-7
31. 31 Morganti G, Gianferrari L, Cresseri A, Arrigoni G, Glovati G. Recherches clinico-statistiques et genetiques sur les neoplasies de la prostate. Acta Genet 1956; 6: 304-5
32. 32 Woolf C. An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960; 13: 739-44
33. 33 Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1982; 1: 47-69
34. 34 Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337-47
35. 35 Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systemic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600-8
36. 36 Hayes RB, Liff JM, Pottern LM et al. Prostate cancer risk in U.S blacks and whites with a family history of cancer. Int J Cancer 1995; 60: 361-4
37. 37 Keetch DW, Rice JP, Suarez BK, Catalona WJ. Familial aspects of prostate cancer: a case control study. J Urol 1995; 154: 2100-2
38. 38 Mettlin CM, Natarajan N, Huben R, Raghavan D. Reported family history of cancer in 1,271 prostate cancer cases and 1, 909 controls. Urol Oncol 1995; 1: 240-5
39. 39 Whittemore AS, Wu AH, Kolonel LN et al. Family history and prostate cancer risk in black, white, and Asian men in the united states and Canada. Am J Epidemiol 1995; 141: 732-40
40. 40 Grönberg H, Damber L, Damber J-E. Familial prostate cancer in Sweden, a nationwide register cohort study. Cancer 1996; 77: 138-43
41. 41 Lesko S, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol 1996; 144: 1041-7
42. 42 Rodríguez C, Calle E, Miracle-McMahill H et al. Family history and risk of fatal prostate cancer. Epidemiology 1997; 8: 653-7
43. 43 Cerhan J, Parker A, Putnam S et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 1998; 8: 53-60
44. 44 Monroe K, Yu M, Kolonel L et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nature Med 1995; 1: 827-9
45. 45 Cannon-Albright L, Thomas A, Goldgar D et al. Familiality of cancer in Utah. Cancer Res 1994; 54: 2378-85
46. 46 Ahlbom A, Lichtenstein P, Malmstöm H, Feychting M, Hemminki K, Pedersen N. Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst 1994; 89: 287-93
47. 47 Grönberg H, Damber L, Damber J-E. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152: 1484-9
48. 48 Page W, Braun M, Partin A, Caporaso N, Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997; 33: 240-5
49. 49 Anderson D, Badzioch M. Familial effects of prostate and other cancers on lifetime breast cancer risk. Br Cancer Res Treat 1993; 28: 107-13
50. 50 Sellers TA, Potter JD, Rich SS et al. Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 1994; 86: 1860-5
51. 51 Tulinius H, Olafsdottir GH, Sigvaldason H, Bjarnadottir K. Neoplastic diseases in families of breast cancer patients. J Med Genet 1994; 31: 618-21
52. 52 Damber L, Grönberg H, Damber J-E. Familial prostate cancer and possible associated malignancies: Nation-wide register cohort study in Sweden. Int J Cancer 1998; 78: 293-7
53. 53 Isaacs SD, Kiemeney LALM, Baffoe-Bonnie A, Beaty TH, Walsh PC. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995; 87: 991-6
54. 54 Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-71
55. 55 Grönberg H, Damber L, Damber J-E, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997; 146: 552-7
56. 56 Schaid D, McDonnel S, Blute M, Thibodeau S. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998; 62: 1425-38
57. 57 Smith JR, Freije D, Carpten JD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371-4
58. 58 Cooney K, McCarthy J, Lange E et al. Prostate cancer susceptibility locus on chromosome 1Q: a confirmatory study. J Natl Cancer Inst 1997; 89: 955-99
59. 59 Hsieh C-L, Oakley-Girvan I, Gallagher R et al. Prostate cancer susceptibility locus on chromosome 1Q: a confirmatory study (letter). J Natl Cancer Inst 1997; 89: 1893
60. 60 Eeles R, Durocher F, Edwards F et al. Linkage analysis of chromosome 1Q markers in 136 prostate cancer families. Am J Hum Genet 1998; 62: 653-8
61. 61 Berthon P, Valeri A, Cohen-Akenine A et al. Predisposing gene for early-onset prostate cancer, located on chromosome 1q42.2-43. Am J Hum Genet 1998; 62: 1416-24
62. 62 McIndoe R, Stanford J, Gibbs M et al. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Gen 1997; 61: 347-53
63. 63 Grönberg H, Xu J, Smith J et al. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res 1997; 57: 4707-9
64. 64 Grönberg H, Isaacs S, Smith J et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997; 278: 1251-5
65. 65 Isaacs W, Bova G. Prostate cancer. The Genetic Basis of Human Cancer. New York: McGraw-Hill, 1998: 653-60
66. 66 Dunsmuir W, Edwards S, Lakhani S et al. Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. Br J Cancer 1998; 78: 1430-3
67. 67 Latil A, Cussenot O, Fournier G, Lidereau R. Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours (letter). Int J Cancer 1997; 71: 118
68. 68 Narod SA, Feunteun J, Lynch HT. Familial breast cancer locus on chromosome 17q21. Lancet 1995; 338: 82-3
69. 69 Xu J, Meyers D, Freije D et al. Evidence for a prostate cancer susceptibility locus on the X chromosome (letter). Nature Genetics 1998; 20: 175-9
70. 70 Gibbs M, Stanford J, McIndoe R et al. Evidence for a rare prostate cancer susceptibility locus at chromosome 1p36. Am J Hum Genet 1999; 64: 776-87
71. 71 Arason A, Barkardóttir RB, Egilsson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostate cancer. Am J Hum Genet 1993; 52: 711-7
72. 72 Gudmundsson J, Johannesdottir G, Arason A et al. Frequent occurrence of a BRCA2 linkage in Icelandic Breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 1996; 58: 749-56
73. 73 Sigurdsson S, Thorlacius S, Tomasson J et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997; 75: 758-61
74. 74 Ford D, Easton DF, Bishop DT et al. Risk of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692-5
75. 75 Thorlacius S, Struewing J, Hartge P et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352: 1337-9
76. 76 Easton D, Steele L, Fields P et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997; 61: 120-8
77. 77 Struewing J, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-8
78. 78 Uchida T, Wang C, Sato T et al. BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer. Int J Cancer (Pred Oncol) 1999; 84: 19-23
79. 79 Lehrer S, Fodor F, Stock R et al. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998; 78: 771-3
80. 80 Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, Ostrander EA. Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 1996; 58: 881-5
81. 81 Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI. Pathological features of hereditary prostate cancer. J Urol 1995; 153: 987-92
82. 82 Bauer J, Srivastava S, Connelly R et al. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998; 51: 970-6
83. 83 Bova G, Partin A, Isaacs S et al. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 1998; 160: 660-3
84. 84 Kupelian P, Klein E, Witte J, Kupelian V, Suh J. Familial prostate cancer: a different disease? J Urol 1997; 158: 2197-201
85. 85 Kupelian P, Kupelian V, Witte J, Macklis R, Klein E. Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 1997; 15: 1478-80
86. 86 Hanlon A, Hanks G. Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology 1998; 52: 735-8
87. 87 Hanus M, Zagars G, Pollack A. Familial prostate cancer: outcome following radiation therapy with and without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys 1999; 43: 379-83
88. 88 Grönberg H, Damber L, Tavelin B, Damber J-E. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998; 82: 564-7
89. 89 Bratt O, Kristoffersson U, Olsson H, Lundgren R. Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor. Eur Urol 1998; 34: 19-24
90. 90 Aprikian AG, Zhang Z-F, Fair WR. Prostate adenocarcinoma in men younger than 50 years. Cancer 1994; 74: 1768-77
91. 91 Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama Y. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998; 82: 531-7
92. 92 Bratt O, Kristoffersson U, Lundgren R, Olsson H. Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing. Urology 1997; 50: 360-5
93. 93 Kerlikowske K, Grady D, Rubin S, Sandrock C, Ernster V. Efficacy of screening mammography: a meta-analysis. JAMA 1995; 273: 149-54
94. 94 Schröder F, van der Maas P, Beemserboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998; 90: 1817-23
95. 95 Stenman U-H, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alfa-1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 334: 1594-8
96. 96 Altman D. Practical Statistics for Medical Research. London: Chapman & Hall 1991
97. 97 Aprikian A, Bazinet M, Plante M et al. Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 1995; 154: 404-6
98. 98 Krain L. Some epidemiological variables in prostatic carcinoma in California. Prev Med 1974; 3: 154-9
99. 99 Schuman L, Mandel J, Bauer H, Scarlett J, McHugh R. Epidemiologic study of prostatic cancer: a preliminary report. Cancer Treat Rep 1977; 61: 181-6
100. 100 Meikle AW, Smith JA, West DW. Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate 1985; 6: 121-8
101. 101 Fincham S, Hill G, Hanson J, Wijayasinghe C. Epidemiology of prostate cancer: a case-control study. Prostate 1990; 17: 189-206
102. 102 Ghadirian P, Cadotte M, Lacroix A, Perret C. Family aggregation of cancer of the prostate in Quebec: the tip of the iceberg. Prostate 1991; 19: 43-52
103. 103 Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a case control analysis. J Urol 1991: 146: 1305-7
104. 104 McCahy P, Harris C, Neal D. Breast and prostate cancer in the relatives of men with prostate cancer. Br J Urol 1996; 78: 552-6
105. 105 Ghadirian P, Howe G, Hislop T, Maisonneuve P. Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer 1997; 70: 679-81
106. 106 Bratt O, Kristoffersson U, Lundgren R, Olsson H. The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: a population-based cohort study. Eur J Cancer 1997; 33: 2237-40
107. 107 Glover F, Coffey D, Douglas L et al. Familial study of prostate cancer in Jamaica. Urology 1998; 52: 441-3